RPRX — Royalty Pharma plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1802768 ·
Last close
$68.68
Market Cap
$30.58B
52W High
$70.13
52W Low
$36.68
ADV30
3,378,290
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 690,103,000 — 561,197,000 144,675,000 19,461,223,000 513,657,000 9,665,952,000
Jun 2026 674,141,000 — 133,119,000 17,883,000 19,819,771,000 811,986,000 10,034,057,000
Mar 2026 630,576,000 — 632,481,000 294,690,000 19,815,415,000 586,395,000 9,878,582,000
Dec 2025 621,990,000 — 388,382,000 214,205,000 19,620,780,000 618,696,000 9,905,841,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,959,918,000
Investing CF
$-1,841,052,000
Financing CF
$-1,544,153,000
CapEx
—
Dividends Paid
$-408,865,000
Buybacks
$-261,618,000
EPS Diluted TTM
$1.41
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$2,498,713,000
Inventory
—
Receivables
$35,931,000
ST Investments
$968,078,000
EBIT TTM
$1,544,296,000
Pretax Income TTM
$1,172,292,000
Interest Exp TTM
$372,004,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,616,809,984
EBITDA
$1,690,461,056
Free Cash Flow
$-450,273,632
Enterprise Value
$40,967,372,800
Total Cash
$544,857,024
Total Debt
$8,587,494,912
Shares Out
445,265,805
Trailing EPS
$1.53
Book Value
$15.34
ROE
12.1%
ROA
5.4%
Div Yield
1.40%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,378,193,000 1,559,518,000 770,947,000 19,620,780,000 9,905,841,000 6,476,900,000 2,489,823,000
Dec 2024 2,263,576,000 1,292,444,000 858,983,000 18,222,715,000 7,880,349,000 6,946,581,000 2,768,986,000
Dec 2023 2,354,554,000 1,492,150,000 1,134,834,000 16,381,851,000 6,297,562,000 6,526,497,000 2,987,802,000
Dec 2022 2,237,215,000 922,892,000 42,832,000 16,813,466,000 7,288,093,000 5,628,150,000 2,143,980,000

TTM Snapshot

Revenues TTM
$2,535,998,000
NetIncome TTM
$814,995,000
OpCashFlow TTM
—
Assets (Latest)
$19,819,771,000
Forward EPS
$5.91

Max Pain — expiry 2026-12-18

max pain strike: $45.00 · spot: $68.67 · call oi: 4,083 · put oi: 154

Peers — same industry

TickerNameMarket CapLastDaily %
GMAB GENMAB A/S $31.95B $51.96 —
ROIV Roivant Sciences Ltd. $28.05B $38.71 —
ZTS Zoetis Inc. $33.92B $83.48 —
INSM INSMED Inc $26.73B $121.86 —
UTHR UNITED THERAPEUTICS Corp $24.88B $584.10 —

News headlines (Yahoo Finance, 1h cache)

Royalty Pharma to present at the UBS Global Biopharma Conference
2026-11-12 21:15 · Yahoo
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
2026-11-10 13:47 · Yahoo
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
2026-11-08 15:35 · Yahoo
How Investors Are Reacting To Royalty Pharma (RPRX) Earnings Beat
2026-11-06 22:14 · Yahoo
Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
2026-11-06 16:00 · Yahoo
Royalty Pharma (RPRX) Stock Looks Fully Valued After A 168% Run
2026-11-06 08:15 · Yahoo
Can Royalty Pharma (RPRX) Justify Its Price Following A Third Straight Guidance Raise?
2026-11-06 01:18 · Yahoo
Royalty Pharma PLC (RPRX) (Q3 2026) Earnings Call Highlights: Raised Guidance, Strong Royalty ...
2026-11-05 01:06 · Yahoo
Royalty Pharma plc Q3 2026 Earnings Call Summary
2026-11-04 23:21 · Yahoo
Royalty Pharma Q3 Earnings Call Highlights
2026-11-04 20:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.